Fox Chase Cancer Center Researchers See Reduced Immune-Related Side Effects With Nivolumab
PHILADELPHIA (September 7, 2023) — Researchers at Fox Chase Cancer Center have published the results of a phase 1 study that showed that the cytokine interferon-gamma may help reduce serious immune-related adverse events that can occur with the use of the immune checkpoint inhibitor drug nivolumab.